Loading...
Please wait, while we are loading the content...
Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.
| Content Provider | Europe PMC |
|---|---|
| Author | Doi, Toshihiko Shitara, Kohei Kojima, Takashi Kuboki, Yasutoshi Matsubara, Nobuaki Bando, Hideaki Yoh, Kiyotaka Naito, Yoichi Hirai, Hiroshi Kurokawa, Yukinori Kato, Terufumi Morizane, Chigusa |
| Page Count | 12 |
| ISSN | 13479032 |
| Volume Number | 114 |
| PubMed Central reference number | PMC9899610 |
| Issue Number | 2 |
| PubMed reference number | 35838190 |
| Journal | Cancer Science [Cancer Sci] |
| e-ISSN | 13497006 |
| DOI | 10.1111/cas.15486 |
| Language | English |
| Publisher | John Wiley and Sons Inc. |
| Publisher Date | 2022-12-04 |
| Publisher Place | Hoboken |
| Access Restriction | Open |
| Rights License | This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. |
| Subject Keyword | FGFR futibatinib gastric cancer phase 1 TAS‐120 |
| Content Type | Text |
| Resource Type | Article |
| Subject | Cancer Research Oncology |